Possible role of vascular risk factors in Alzheimer's disease and vascular dementia

Current Pharmaceutical Design

Volumn 20, Issue 38, 2014, Pages 6007-6013

  Hasnain, Mehrul ^a   Vieweg, W Victor R ^b  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Adiposity; Alzheimer s disease; Diabetes mellitus; Dyslipidemia; Hypertension; Physical activity; Vascular dementia; Vascular risk factors

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPID;

ALZHEIMER DISEASE; ARTICLE; ATTRIBUTABLE RISK; COGNITION; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; EXERCISE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN RESISTANCE; MEDLINE; MULTIINFARCT DEMENTIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK FACTOR; SMOKING; ADVERSE EFFECTS; ANIMAL; DEMENTIA, VASCULAR; PSYCHOLOGY; RISK REDUCTION;

ALZHEIMER DISEASE; ANIMALS; DEMENTIA, VASCULAR; HUMANS; HYPERTENSION; OBESITY; RISK FACTORS; RISK REDUCTION BEHAVIOR; SMOKING;

EID: 84925320721     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140314153440     Document Type: Article

References (80)

1. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366(9503): 2112-7.
2. Fotuhi M, Hachinski V, Whitehouse PJ. Changing perspectives regarding late-life dementia. Nat Rev Neurol 2009; 5(12): 649-58.
3. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 2010; 120(3): 287-96.
4. de la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 2004; 3(3): 184-90.
5. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999; 100(13): 1481-92.
6. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42(9): 2672-713.
7. Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev 2011; 12(5): e426-e437.
8. Xu WL, Atti AR, Gatz M, Pedersen NL, Johansson B, Fratiglioni L. Midlife overweight and obesity increase late-life dementia risk: a population-based twin study. Neurology 2011; 76(18): 1568-74.
9. Dahl AK, Hassing LB, Fransson EI, Gatz M, Reynolds CA, Pedersen NL. Body mass index across midlife and cognitive change in late life. Int J Obes (Lond) 2012.
10. Power BD, Alfonso H, Flicker L, Hankey GJ, Yeap BB, Almeida OP. Body adiposity in later life and the incidence of dementia: the health in men study. PLoS One 2011; 6(3): e17902.
11. Luchsinger JA, Cheng D, Tang MX, Schupf N, Mayeux R. Central obesity in the elderly is related to late-onset alzheimer disease. Alzheimer Dis Assoc Disord 2012; 26(2): 101-5.
12. Stewart R, Masaki K, Xue QL, et al. A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol 2005; 62(1): 55-60.
13. Buchman AS, Wilson RS, Bienias JL, Shah RC, Evans DA, Bennett DA. Change in body mass index and risk of incident Alzheimer disease. Neurology 2005; 65(6): 892-7.
14. Kennelly SP, Lawlor BA, Kenny RA. Blood pressure and the risk for dementia: a double edged sword. Ageing Res Rev 2009; 8(2): 61-70.
15. Nagai M, Hoshide S, Kario K. Hypertension and dementia. Am J Hypertens 2010 Feb; 23(2): 116-24.
16. Sharp SI, Aarsland D, Day S, Sonnesyn H, Ballard C. Hypertension is a potential risk factor for vascular dementia: systematic review. Int J Geriatr Psychiatry 2011; 26(7): 661-9.
17. Duron E, Hanon O. Antihypertensive treatments, cognitive decline, and dementia. J Alzheimers Dis 2010; 20(3): 903-14.
18. Chang-Quan H, Hui W, Chao-Min W, et al. The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta-analysis of longitudinal studies. Int J Clin Pract 2011; 65(12): 1295-305.
19. Johnson ML, Parikh N, Kunik ME, et al. Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. Alzheimers Dement 2012; 8(5): 437-44.
20. McGuinness B, Todd S, Passmore AP, Bullock R. Systematic review: Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. J Neurol Neurosurg Psychiatry 2008; 79(1): 4-5.
21. Bourdel-Marchasson I, Lapre E, Laksir H, Puget E. Insulin resistance, diabetes and cognitive function: consequences for preventative strategies. Diabetes Metab 2010; 36(3): 173-81.
22. Reijmer YD, van den Berg E, Ruis C, Kappelle LJ, Biessels GJ. Cognitive dysfunction in patients with type 2 diabetes. Diabetes Metab Res Rev 2010; 26(7): 507-19.
23. Okereke OI, Kang JH, Cook NR, et al. Type 2 diabetes mellitus and cognitive decline in two large cohorts of community-dwelling older adults. J Am Geriatr Soc 2008; 56(6): 1028-36.
24. Carlsson CM. Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease. J Alzheimers Dis 2010; 20(3): 711-22.
25. Luchsinger JA. Type 2 diabetes, related conditions, in relation and dementia: an opportunity for prevention? J Alzheimers Dis 2010; 20(3): 723-36.
26. Cheng G, Huang C, Deng H, Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J 2012; 42(5): 484-91.
27. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP, Jr., Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009 Apr 15; 301(15): 1565-72.
28. Exalto LG, Whitmer RA, Kappele LJ, Biessels GJ. An update on type 2 diabetes, vascular dementia and Alzheimer's disease. Exp Gerontol 2012; 47(11): 858-64.
29. Panza F, Frisardi V, Seripa D, et al. Metabolic syndrome, mild cognitive impairment, and dementia. Curr Alzheimer Res 2011; 8(5): 492-509.
30. Kloppenborg RP, van den Berg E, Kappelle LJ, Biessels GJ. Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur J Pharmacol 2008; 585(1): 97-108.
31. Shoji T, Hatsuda S, Tsuchikura S, et al. Small dense low-density lipoprotein cholesterol concentration and carotid atherosclerosis. Atherosclerosis 2009; 202(2): 582-8.
32. Raffaitin C, Gin H, Empana JP, et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care 2009; 32(1): 169-74.
33. Perlmuter LC, Nathan DM, Goldfinger SH, Russo PA, Yates J, Larkin M. Triglyceride levels affect cognitive function in noninsulin-dependent diabetics. J Diabet Complications 1988; 2(4): 210-3.
34. Bonarek M, Barberger-Gateau P, Letenneur L, et al. Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study. Neuroepidemiology 2000; 19(3): 141-8.
35. Fonseca AC, Resende R, Oliveira CR, Pereira CM. Cholesterol and statins in Alzheimer's disease: current controversies. Exp Neurol 2010; 223(2): 282-93.
36. Razay G, Vreugdenhil A, Wilcock G. The metabolic syndrome and Alzheimer disease. Arch Neurol 2007; 64(1): 93-6.
37. Reitz C. Dyslipidemia and the risk of Alzheimer's disease. Curr Atheroscler Rep 2013; 15(3): 307.
38. Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol 2011; 68(11): 1385-92.
39. Middleton LE, Barnes DE, Lui LY, Yaffe K. Physical activity over the life course and its association with cognitive performance and impairment in old age. J Am Geriatr Soc 2010; 58(7): 1322-6.
40. Ahlskog JE, Geda YE, Graff-Radford NR, Petersen RC. Physical exercise as a preventive or disease-modifying treatment of dementia and brain aging. Mayo Clin Proc 2011; 86(9): 876-84.
41. Snowden M, Steinman L, Mochan K, et al. Effect of exercise on cognitive performance in community-dwelling older adults: review of intervention trials and recommendations for public health practice and research. J Am Geriatr Soc 2011; 59(4): 704-16.
42. Lautenschlager NT, Cox K, Kurz AF. Physical activity and mild cognitive impairment and Alzheimer's disease. Curr Neurol Neurosci Rep 2010; 10(5): 352-8.
43. Smith PJ, Blumenthal JA, Hoffman BM, et al. Aerobic exercise and neurocognitive performance: a meta-analytic review of randomized controlled trials. Psychosom Med 2010; 72(3): 239-52.
44. Sofi F, Valecchi D, Bacci D, et al. Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. J Intern Med 2011; 269(1): 107-17.
45. Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychol Med 2009; 39(1): 3-11.
46. Morgan GS, Gallacher J, Bayer A, Fish M, Ebrahim S, Ben-Shlomo Y. Physical activity in middle-age and dementia in later life: findings from a prospective cohort of men in caerphilly, South wales and a meta-analysis. J Alzheimers Dis 2012; 31(3): 569-80.
47. Aarsland D, Sardahaee FS, Anderssen S, Ballard C. Is physical activity a potential preventive factor for vascular dementia? A systematic review. Aging Ment Health 2010; 14(4): 386-95.
48. Almeida OP, Hulse GK, Lawrence D, Flicker L. Smoking as a risk factor for Alzheimer's disease: contrasting evidence from a systematic review of case-control and cohort studies. Addiction 2002; 97(1): 15-28.
49. Peters R, Poulter R, Warner J, Beckett N, Burch L, Bulpitt C. Smoking, dementia and cognitive decline in the elderly, a systematic review. BMC Geriatr 2008; 8: 36.
50. Anstey KJ, von SC, Salim A, O'Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol 2007; 166(4): 367-78.
51. Rusanen M, Kivipelto M, Quesenberry CP, Jr., Zhou J, Whitmer RA. Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch Intern Med 2011; 171(4): 333-9.
52. Solfrizzi V, Scafato E, Capurso C, et al. Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing. J Neurol Neurosurg Psychiatry 2010; 81(4): 433-40.
53. Frisardi V, Imbimbo BP. Metabolic-cognitive syndrome: metabolic approach for the management of Alzheimer's disease risk. J Alzheimers Dis 2012; 30 Suppl 2: S1-4.
54. Panza F, Solfrizzi V, Logroscino G, et al. Current epidemiological approaches to the metabolic-cognitive syndrome. J Alzheimers Dis 2012; 30 Suppl 2: S31-75.
55. Leszek J, Sochocka M, Gasiorowski K. Vascular factors and epigenetic modifications in the pathogenesis of Alzheimer's disease. J Neurol Sci 2012; 323(1-2): 25-32.
56. NIH State-of-the-Science Conference. Preventing Alzheimer's Disease and Cognitive Decline. http://consensus. nih. gov/2010/alzstatement. htm Last accessed May 4, 2014.
57. Flicker L, Liu-Ambrose T, Kramer AF. Why so negative about preventing cognitive decline and dementia? The jury has already come to the verdict for physical activity and smoking cessation. Br J Sports Med 2011; 45(6): 465-7.
58. Jellinger KA, Mitter-Ferstl E. The impact of cerebrovascular lesions in Alzheimer disease-a comparative autopsy study. J Neurol 2003; 250(9): 1050-5.
59. Lewis H, Beher D, Cookson N, et al. Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. Neuropathol Appl Neurobiol 2006; 32(2): 103-18.
60. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277(10): 813-7.
61. Stephan BC, Matthews FE, Ma B, et al. Alzheimer and vascular neuropathological changes associated with different cognitive States in a non-demented sample. J Alzheimers Dis 2012; 29(2): 309-18.
62. Shah NS, Vidal JS, Masaki K, et al. Midlife blood pressure, plasma beta-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study. Hypertension 2012; 59(4): 780-6.
63. Seo SW, Lee JM, Im K, et al. Cardiovascular risk factors cause cortical thinning in cognitively impaired patients: relationships among cardiovascular risk factors, white matter hyperintensities, and cortical atrophy. Alzheimer Dis Assoc Disord 2012; 26(2): 106-12.
64. Vuorinen M, Solomon A, Rovio S, et al. Changes in vascular risk factors from midlife to late life and white matter lesions: a 20-year follow-up study. Dement Geriatr Cogn Disord 2011; 31(2): 119-25.
65. World Health Organization. Dementia: a public health priority. http://www. who. int/mental_health/publications/dementia_report_2012/e n/index. html. Last accessed May 4, 2014.
66. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 2011; 10(9): 819-28.
67. Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: how to move forward? Neurology 2009; 72(4): 368-74.
68. Brown BM, Peiffer JJ, Taddei K, et al. Physical activity and amyloid-beta plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Mol Psychiatry 2012 Aug 14.
69. de la Torre JC. Vascular risk factor detection and control may prevent Alzheimer's disease. Ageing Res Rev 2010; 9(3): 218-25.
70. Glynn LG, Murphy AW, Smith SM, Schroeder K, Fahey T. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev 2010; (3): CD005182.
71. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011; 343: d6898.
72. Newhouse P, Kellar K, Aisen P, et al. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology 2012; 78(2): 91-101.
73. Tortosa-Martinez J, Clow A. Does physical activity reduce risk for Alzheimer's disease through interaction with the stress neuroendocrine system? Stress 2012; 15(3): 243-61.
74. Bomboi G, Castello L, Cosentino F, Giubilei F, Orzi F, Volpe M. Alzheimer's disease and endothelial dysfunction. Neurol Sci 2010; 31(1): 1-8.
75. Chuang YF, Hayden KM, Norton MC, et al. Association between APOE epsilon4 allele and vascular dementia: The Cache County study. Dement Geriatr Cogn Disord 2010; 29(3): 248-53.
76. Grammas P. Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. J Neuroinflammation 2011; 8: 26.
77. Irie F, Fitzpatrick AL, Lopez OL, et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. Arch Neurol 2008; 65(1): 89-93.
78. Kerola T, Kettunen R, Nieminen T. The complex interplay of cardiovascular system and cognition: how to predict dementia in the elderly? Int J Cardiol 2011; 150(2): 123-9.
79. Lee EB. Obesity, leptin, and Alzheimer's disease. Ann N Y Acad Sci 2011; 1243: 15-29.
80. Levine DA, Langa KM. Vascular cognitive impairment: disease mechanisms and therapeutic implications. Neurotherapeutics 2011; 8(3): 361-73.